AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca saphnelo (anifrolumab) — Established RoW YoY actual (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, FY2025
52.0%
Period ended Dec 31, 2025
Change on a year earlier
-17.0 pts
69.0% in FY2024
History
3 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Saphnelo (anifrolumab) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.0% | -17.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 69.0% | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 0.0% | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Saphnelo (anifrolumab) — Established RoW YoY actual (%) (%), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_saphnelo_erow_act_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.